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INTRODUCTION
Adherence to therapy is a key aspect in determining the efficacy of a given drug in the clinical practice. Adherence may be defined as the extent to which patient's behavior (in terms of taking medication, following a diet, modifying habits, or attending clinics) coincides with medical or health advice.
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Adherence to treatment is generally optimal in short term diseases, which are characterized by a predictable course and a rapid resolution after introduction of therapeutic, on the other hand, chronic diseases with an unpredictable course, long periods of low activity and the need for lifelong medication are frequently related with non-adherence behaviors. lifelong treatment. These diseases represent a high risk situation for non-adherence: a chronic illness, affecting young patients, with an unpredictable course, with naturallyoccurring long inactive periods, and sometimes managed by non-convenient or difficult-to-follow therapies. [3] [4] [5] On the other hand, poor adherence may result in more frequent relapses, a disabling disease course, increases in the frequency of hospital admissions and an overall rise in healthcare costs. 6, 7 With these outcomes, it is now even more important to understand the factors involved with non-adherence behavior and identify which patients are at highest risk, so that intervention can occur early.
The aim of our study was to evaluate the frequency of nonadherence to the treatment among ambulatory patients with IBD and to study which factors could influence it.
MATERIAL AND METHODS
Patients with the diagnosis of IBD, followed up in the Gastroenterology Department at Centro Hospitalar do Alto Ave, Guimarães, were prospectively interviewed during an outpatient specialist visit using a questionnaire.
The patients were informed about adherence problems and the study's character. They were assured that the responses in no way will influence their further treatment options and those who agreed with participation were enrolled and signed the informed consent.
A written interview was done, anonymously and without the presence of any of the treating physicians. Some patients with difficulties to understand the questionnaire had help from a gastroenterology nurse. We excluded patients seen for the first time, in urgent context, treated with monotherapy with biological agents and those unable to fill up the questionnaire.
The questionnaire included 23 questions regarding: 1) demographic data: age, gender, studies and working status, 2) data on the disease character: type of IBD, year of diagnosis, number of hospital admissions, and number of IBD-related surgical procedures, 3) data on their treatment: drugs and type (oral vs. topical), 4) adherence to treatment, 5) how often the medication was forgotten (rarely, sometimes, often, very often), 6) number of doses usually forgotten every week during the year preceding the survey, and reason for forgetting them, 7) smoking habits, and 8) complementary and alternative medicine (CAM) use.
In our study, patients were considered to be non-adherent if they forgot at least a dose a week, often or very often, during the last 12 months.
Statistical Methods
Using the Gpower ® software and taken into consideration the statistical tests employed, we determined the minimum sample size to be eighty patients.
Data were analyzed with SPSS 18.0. For continuous variables, mean and standard deviation were calculated. For categorical variables, percentages were provided. Categorical variables were compared with Chi-square test, and in cases where the premises of this test were not met (no more than 20% of cells with expected frequencies less than 5) was used the Fisher's exact test. A p value < 0.05 was considered statistically significant. Binary logistic regression was used to determine the association between demographic variables and Table 1 Age, mean ± SD* (min-max) ≤ 30 years, n (%) > 30 years, n (%) 
RESULTS
A total of 138 consecutive IBD patients were interviewed. The questionnaire was correctly filled up by 100% of patients, but two of them with nurse help. Main clinical characteristics of the study population are shown in Table 1 .
In this sample, 29.7% (n = 41) of the patients reported nonadherence to their treatment, 16 of those with UC and 25 of those with CD. As there was no apparent difference between the two diseases in terms of adherence, they were considered together in the subsequent analysis.
Involuntary non-adherence behavior (simple forgetfulness) was reported in 29 (70.7%) patients. The voluntary non-adherence was observed in 12 (29.3%) patients. The most common causes of voluntary non-adherence: too many/ unnecessary drugs in 7 (17.1%) patients; being afraid of side effects in 4 (9.8%) patients and complicated administration of topical aminosalicylates in 1 (2.4%) patient. Twenty one (51.2%) patients revealed a behavior of non-adherence at least one dose a week; 8 (19,5%) patients forgot two doses a week; 9 (22.0%) patients forgot three doses a week and 3 (7.3%) patients were non-adherent four or more doses per week.
Non-adherence was statistically associated with: short disease duration (p < 0.001), young age (p = 0.001), therapy with topical aminosalicylates (p = 0.005), the perception that medical therapy isn't effective enough (p = 0.007) and high educational level (p = 0.011) (Table2). On the other hand, different factors such as gender (p = 1.000), disease type (p = 0.458), smoker status (p = 1.000), occurrence of minor side effects (p = 0.635), use of alternative medicine (p = 1.000), previous IBD-related admissions (p = 1.000), previous surgeries (p = 0.619); unemployment status (p = 0.349) and therapy (oral aminosalicylates p = 1.000; azathioprine p = 0.854; steroids p = 0.436) did not correlate with the degree of adherence.
In a logistic regression analysis, the topical aminosalicylates use (p = 0.004), the short disease duration (p = 0.006) and young age (p = 0.027) were identified as significant predictors of non-adherence to treatment (Table 3) .
DISCUSSION
The causes of medication non-adherence are complex, where the patient-doctor relationship, treatment regimen, and other disease-related factors play key roles. Non-adherence is significant whenever it determines a change in the therapeutic effect intended with the drug prescribed.
Clinical trials reporting efficacy and safety of treatment therapies available in the management of IBD have reported patient adherence rates of between 70% and 95%. 8, 9 However, trials are an ideal situation, in which therapy supervision is more intense than usual. In real life treatment adherence is lower, with percentage of non-adherent patients ranging between 38% to 70%. 3, [9] [10] [11] [12] [13] In our work we found a lower percentage of non-adherent behavior (29.7%), even so, a significant number of our patients are not benefiting from the full potential of their therapy. There is no gold standard method to measure adherence, but interview and questionnaire methods are most commonly used because they are easy to obtain and inexpensive. These questionnaires are susceptible to underrepresentation and tend to overestimate adherence, but they detect most non-adherent patients.
14 Although we used a questionnaire to assess the medication-taking behavior, it was conducted according to general standards to increase valid responses (i.e., nonjudgmental questions were used and confidentiality was emphasized).
Differentiating voluntary non-adherence and involuntary non-adherence (simple forgetfulness) is useful to be able to define a strategy aiming a correction of the problem. Bermejo et al 13 describe 66% of some involuntary non-adherence. The involuntary non-adherence that we report in our study is similar (70.7%). In these patients is possible that adherence may be improved with different strategies, such as setting alarms on watches⁄mobile phones or traditional reminders (placing pills close to something they use daily, e.g. the toothpaste, breakfast table, glasses or contact lenses case, night-time beverage, etc.). 15 As in other studies, 3,13,16 voluntary non-adherence was less frequent (29.3%), but its significance greater, because it represents an active decision by the patient. Education of patients is a key to reverse this situation, because it may address unrealistic fears and associations the patient has with their medication.
Age seems to be an important factor, as younger patients tend to be less adherent than older patients.
3,16 D'Inca et al 16 reported that non-adherence was 43% in patients < 40 years old compared to 34% in those older than 40 years (p = 0.041). Diagnosis and disease duration shorter than 5 years was also associated with significantly worse adherence (24% of the patients) than a longer-standing disease (15% of the patients) in the same study. In the present study, both young age and short disease duration were also associated with higher nonadherence rates. This may be related to the fact that IBD primarily affects young individuals with greater personal and social goals, being busy at work, and having some degree of rebelliousness, but it may also be that a younger age is associated with a more recent diagnosis, with less experience with the burden of relapse.
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Our study found that topical therapy with enemas, suppositories or foams was significantly associated with non-adherence in univariate analysis (p = 0.005) and in logistic regression model (p = 0.004). In this group of patients, the voluntary behavior (8 patients, 61.5% of nonadherent patients) was the main reason for non-adherence to treatment, and although only one patient refer the complicated administration of topical aminosalicylates as the main cause for this behavior, a significant number of this patients reported too many/unnecessary drugs (4 patients, 30.7%) and being afraid of side effects (3 patients, 23.1%). Previous studies have also reported that non-adherence to therapy might also be due not only to the drug formulation causing discomfort (difficulty in swallowing tablets or using enemas) but also to the side effects (pain or abdominal distension, difficulty in retaining enemas).
In the present study, we did not find an association between the drug type (oral aminosalicylates p = 1.000, steroids p = 0.436 and azathioprine p = 0.854) and medical adherence, It should be noted that our study assesses self-report of typical medication adherence, it does not directly assess adherence behavior in the context of a specific treatment as a pill count would. We also did not report the adherence data for Anti-TNF monotherapy, as compliance therapy in these patients is closely monitored in our department.
A higher education level was associated with a nonadherent patient behavior in some, but not all studies. 10, 12, [18] [19] [20] We found an association between high educational level and non-adherence to treatment (p = 0.011), but in logistic regression model this variable showed no predict ability on non-adherence to treatment.
As reported in this study a patient perception of benefits derived from therapy was associated with adherence to treatment in univariate analysis (p = 0.007), but without significant predictive value on logistic regression model. In the study of Shale et al 18 perceiving medication as ineffective was also related to non-adherent behavior. Lack of knowledge of how the medication works and patients' beliefs may be at the origin of this behavior. Patients need to be informed, This study considered many of the important variables related to non-adherence to therapy, however, not all of them could be included. Unfortunately, we could not look for any relationship between non-adherence and disease activity or extent because we adopted a self-administered questionnaire and the patients' perception of disease activity and/or their knowledge of the extent of their disease could be inaccurate. The potential synergistic effect of the presence of other co-morbidities, with particular interest in other chronic diseases, has not also been studied. Future studies should not only include these variables, but also involve other methods to assess adherence. The combination of self-report questionnaires and the administrative data that document prescription refills will allow a more reliable measurement of treatment adherence. 
CONCLUSION
In summary, we may consider that adherence to therapy in IBD patients is insufficient, and parallels what has been described in other studies. Failure to take medication as prescribed increases the risk that patients will not get the intended benefit, often leading to more frequent relapses and resulting in higher healthcare costs. So, understanding the different patient types, the reasons given by patients for non-adherence, dynamic communication within the healthcare team, educational programs and identifying the predictors of non-adherence, will help devise suitable plans to optimize patient adherence.
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